Diamedica Therapeutics INC Form 4 insider transactions

Director James T. Parsons acquires shares and stock options in DiaMedica Therapeutics Inc.

Director Randall Michael Giuffre acquired 10,861 shares of DiaMedica Therapeutics through the settlement of deferred stock units.

Director Richard Kuntz acquired 9,925 shares of DiaMedica Therapeutics Inc. through a restricted stock unit award in lieu of cash retainer fees.

Director Richard D. Pilnik acquired 10,393 shares of DiaMedica Therapeutics Inc. in lieu of cash retainer fees, increasing his total holdings to 288,995 shares.

Director Charles Pauling Semba acquired 5,290 shares of DiaMedica Therapeutics through a restricted stock unit award in lieu of cash retainer fees.

Thomas Von Koch, a director and 10% owner of DiaMedica Therapeutics, indirectly purchased 1,200,000 shares of DMAC at $2.50 per share on June 28, 2024.

Jan Stahlberg, through Trill AB, acquires 1,200,000 common shares of DiaMedica Therapeutics at $2.50 per share, increasing their total holdings.

David J. Wambeke, Chief Business Officer of DiaMedica Therapeutics, reports acquisition of stock options.

DiaMedica Therapeutics' CFO, Scott Kellen, received stock options for 130,000 common shares on June 1, 2024.

Dominic R. Cundari, Chief Commercial Officer of DiaMedica Therapeutics, reports acquisition of stock options and common shares.

DiaMedica Therapeutics' CEO, John Pauls, reports acquisition of stock options and direct ownership of common shares.

Director Charles Pauling Semba reports acquisition of shares and stock options in DiaMedica Therapeutics.

Director Richard D. Pilnik reports acquisition of stock options and updates to beneficial ownership of DiaMedica Therapeutics Inc. shares.

Director James T. Parsons reports acquisition of DiaMedica Therapeutics shares and stock options.

Director Tanya Lewis acquires stock options in DiaMedica Therapeutics, vesting quarterly over one year.

Director Richard Kuntz reports acquisition of stock options and shares from DiaMedica Therapeutics.

Director Randall Michael Giuffre reports acquisition of shares and stock options in DiaMedica Therapeutics.